Shares of ChemoCentryx Inc. (NASDAQ:CCXI) shot up 4.9% during mid-day trading on Friday . The stock traded as high as $4.35 and last traded at $4.31, with a volume of 182,136 shares changing hands. The stock had previously closed at $4.11.

Several brokerages recently issued reports on CCXI. JPMorgan Chase & Co. restated a “buy” rating and issued a $11.00 price objective on shares of ChemoCentryx in a report on Tuesday. Cowen and Company restated a “hold” rating on shares of ChemoCentryx in a report on Thursday, May 19th. Finally, Zacks Investment Research lowered shares of ChemoCentryx from a “buy” rating to a “hold” rating in a report on Monday, May 16th.

The firm’s 50-day moving average is $4.56 and its 200-day moving average is $3.77. The stock’s market capitalization is $191.33 million.

ChemoCentryx (NASDAQ:CCXI) last posted its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by $0.07. On average, analysts anticipate that ChemoCentryx Inc. will post ($0.50) earnings per share for the current year.

In other news, Director Thomas A. Edwards bought 50,000 shares of the stock in a transaction on Tuesday, May 17th. The shares were bought at an average price of $4.05 per share, with a total value of $202,500.00. Following the completion of the acquisition, the director now owns 91,977 shares of the company’s stock, valued at $372,506.85. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas A. Edwards bought 25,000 shares of the stock in a transaction on Monday, May 16th. The stock was purchased at an average cost of $4.05 per share, for a total transaction of $101,250.00. Following the acquisition, the director now directly owns 41,977 shares of the company’s stock, valued at approximately $170,006.85. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in ChemoCentryx stock. Westfield Capital Management Co. LP boosted its stake in shares of ChemoCentryx Inc. (NASDAQ:CCXI) by 1.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,102,332 shares of the biopharmaceutical company’s stock after buying an additional 19,375 shares during the period. Westfield Capital Management Co. LP owned approximately 2.50% of ChemoCentryx worth $8,929,000 as of its most recent SEC filing.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.